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The effect of changes to GOLD severity
stage on long term morbidity and mortality
in COPD
Robert W. V. Flynn*, Thomas M. MacDonald, James D. Chalmers and Stuart Schembri
Abstract
Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) severity stage classifies
Chronic Obstructive Pulmonary Disease (COPD) into groups based on symptoms, exacerbations and forced
expiratory volume in one second (FEV1). This allows patients to change to less severe COPD stages, a novel
aspect of assessment not previously evaluated. We aimed to investigate the association between temporal
changes in GOLD severity stage and outcomes in COPD patients.
Methods: This was a record-linkage study using patients registered with a Scottish regional COPD network 2000–2015.
Annual spirometry & symptoms were recorded and linked to healthcare records to identify exacerbations, hospitalisations
and mortality. Spirometry, modified Medical Research Council (mMRC) dyspnoea scale and acute exacerbations over the
previous year were used to assign GOLD severity at each visit. A time-dependent Cox model was used to model time to
death. Secondary outcomes were respiratory specific mortality and hospitalisations. Effect sizes are expressed as Hazard
Ratios HR (95%CI).
Results: Four thousand, eight hundred and eighty-five patients (mean age 67.3 years; 51.3% female) with 21,348 visits
were included. During a median 6.6 years follow-up there were 1530 deaths. For the secondary outcomes there were 712
respiratory deaths and 1629 first hospitalisations. Across 16,463 visit-pairs, improvement in COPD severity was seen in
2308 (14%), no change in 11,010 (66.9%) and worsening in 3145 (19.1). Compared to patients staying in GOLD stage A,
those worsening had a stepwise increased mortality and hospitalisations.
Conclusions: Improving COPD severity classification was associated with reduced mortality and worsening COPD severity
was associated with increased mortality and hospitalisations. Change in GOLD group has potential as monitoring tool and
outcome measure in clinical trials.
Keywords: Chronic obstructive pulmonary disease, Global initiative for chronic obstructive lung disease (GOLD), Mortality,
Morbidity
Background
Unlike the 2007 Global initiative for Obstructive Lung
Disease (GOLD) chronic obstructive pulmonary disease
(COPD) severity stages that were based solely on Forced
Expiratory Volume in one second (FEV1), the subse-
quent (2011 and beyond) GOLD COPD strategy state-
ments classified COPD severity into distinct groups
based on symptoms and exacerbations as well as spirom-
etry (Fig. 1) [1, 2]. The classification of an individual
patient’s COPD severity using the original GOLD strat-
egy statements criteria would usually remain stable or
indicate more severe disease because the natural pro-
gression of FEV1 often consists of a gradual decline over
time (excluding any initial improvement after starting
long acting bronchodilators or other treatment) [3]. The
mean rate of decline in the ECLIPSE study was 33mls/
year, although there were 8% of patients who increased
their FEV1 by more than 20mls, it is unlikely that many
of these would have improved sufficiently to be classified
as having less severe disease using the previous stratifi-
cation as this used broad percentage of predicted
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cut-offs [4]. However subsequent GOLD severity staging
allowed patients to change to less severe COPD stages
(e.g. D→A in the absence of exacerbations or improv-
ing symptoms) as well becoming more severe. The pos-
sibility of improved COPD severity over time was a
novel aspect of COPD staging that had not been previ-
ously evaluated.
Already published data have shown that the new
GOLD classification could improve the predictive value
over FEV1 alone in relation to some poor outcomes and
symptoms [5–7],; however, many of these studies have
been cross-sectional in nature and several questions re-
garding severity shifts remain unanswered. Previous
studies have looked into the stability of the new GOLD
stages [8–10]; however, the relationship between change
in GOLD stage and patients’ hospitalisations and mortal-
ity remained unclear especially as they move in between
COPD severity stages several times over time.
The 2007 strategy statements were easily applied to
clinical trial inclusion and exclusion criteria as FEV1 is
relatively stable over a short time period. Improving the
understanding of the changing nature of the new GOLD
stages may aid the design of clinical studies aiming at
individualised treatment beyond FEV1 alone.
It was traditionally thought that FEV1 trajectories did
not change substantially with therapy [11] and therefore
changes in GOLD 2007 stage were not an ideal
end-point for clinical trials. With the inclusion of exac-
erbations and symptoms to the 2014 GOLD criteria, it is
now possible to imagine that successful treatment would
“downstage” COPD, by reducing exacerbation frequency
and improving symptoms. We aimed to explore the val-
idity of this concept in a longitudinal community-based
COPD cohort.
This longitudinal observational study sought to estab-
lish whether changes in GOLD 2014 severity stage
correlate with long term outcomes such as all-cause and
respiratory-specific mortality, and respiratory specific
hospital admission in COPD patients. Specifically, we
sought to assess whether there was an association be-
tween change on GOLD stage and time to subsequent
mortality, respiratory mortality and respiratory morbid-
ity. It was designed and funded before the latest GOLD
strategy statements whose severity classification sepa-
rated spirometry from symptoms.
Methods
This was a record-linkage cohort study using databases
from Tayside Scotland. Data from the Tayside Medicines
Monitoring Unit (MEMO) database is held within the
Health Informatics Centre [12]. This system collects data
from the Tayside region of Scotland; a compact geo-
graphical area with a population of over 400,000 people.
Health care for the region is co-ordinated by Tayside
Health Board, which maintains a computerised record of
all patients registered with a general medical practitioner
(GP). In brief, MEMO database contains several datasets
including all dispensed community prescriptions, hos-
pital discharge data, demographic data and biochemistry
results. These data can be linked to disease-specific data-
bases such as TARDIS database (Tayside Allergy and Re-
spiratory Disease Information System) [13] and other
routine clinical data, all of which are linked by a Com-
munity Health Index (CHI) number that is unique to
each patient. All data was anonymised using Cleaning
and Anonymisation by Mapping (CLAM) software and
standard operating procedures (SOPs) as agreed by Tay-
side Committee on Research Medical ethics, Tayside
Caldicott Guardians and research governance.
Data sources
CHI number master patient index – this defined the
study population from which subjects were identified,
providing data on registered Tayside general practi-
tioners, dates registered with general practitioners, date
of birth and date of death.
Scottish Morbidity Records 1 (SMR01) – these data are
routinely validated and collated by the Information and
Services Division (ISD) of the National Health Service in
Scotland and were available for Tayside from January 1,
1980 onwards [12]. These contained diagnostic and pro-
cedural codes relating to all hospital inpatient episodes
of care using the International Classification of Diseases
ninth or tenth revisions (ICD9, ICD10) [14, 15] and Of-
fice of Population Censuses and Surveys Classification of
Interventions and Procedures (OCSP4) [16]. These data
were used to identify respiratory specific hospital admis-
sions during the study period as described below.
TARDIS database – The Tayside Allergy and Respira-
tory Disease Information System has been described
Fig. 1 GOLD severity stage (2014) COPD classification system. AECOPD
– acute exacerbation of COPD; mMRC – modified MRC dyspnoea scale
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before [13, 17]. Since 2001, general practitioners (GPs)
in Tayside have been invited to refer patients in whom
they suspect COPD for screening spirometry. This is
carried out in the GP practices by COPD nurses after
structured training in order to obtain standardized results.
COPD was diagnosed in patients with a FEV1 < 80% of the
predicted value (greatest of pre- and post-bronchodilator
values) and FEV1/forced vital capacity (FVC) < 70% [17].
Those patients in whom COPD is diagnosed are then in-
vited to participate in the structured management
programme called TARDIS. Patients are invited annually
and relevant measures are taken at the same time, includ-
ing the post-bronchodilator FEV1 measure used in this
study. If patients are housebound they are visited at home
annually and this is also recorded in the database. A
six-minute walk test is carried out in patients undergoing
pulmonary rehabilitation.
Study population
The study population was residents of Tayside, Scotland
registered with a general practitioner between 1 January
2001 and 31 December 2015 (the latest date common to
all the data source used). Subjects who left Tayside dur-
ing the study period were censored at that point.
Study subjects
Study subjects had spirometric confirmation of COPD
(FEV1 / FVC < 70%) and were registered with the TAR-
DIS database from January 2001 until the most recent
mortality data available. They were required to be resi-
dent in Tayside for a minimum of 12-months before
their qualifying COPD diagnosis. The date of the pa-
tient’s first annual spirometrically-confirmed COPD visit
was used as the study entry date. Patients who had a
cancer diagnosis prior to the diagnosis of COPD were
excluded from the study (except for non-melanoma skin
cancers). Patients who developed such cancers during
the follow up time were censored 1 year prior to the
diagnosis of cancer. A sensitivity analysis without this
exclusion criteria relating to cancer history was per-
formed. Patients with a single qualifying TARDIS visit
only were excluded because more than one visit was re-
quired to assess change in spirometry and symptoms.
Therefore, two visits with valid spirometry were required
as a minimum for inclusion. This included patients who
had one or more TARDIS visits, but with inadequate
spirometry (FEV1 & FVC) for some visits.
Outcomes
The primary outcome was all-cause mortality. Secondary
outcomes were respiratory specific mortality and hospita-
lisations. Respiratory specific deaths were taken from the
General Register Office (GRO) for Scotland death certifi-
cation database where the primary underlying cause of
death was a respiratory code (ICD10 code J00 – J99). Re-
spiratory hospitalisation was obtained from SMR01, which
contains all records of hospitalisations in Scotland. We in-
cluded admissions coded using ICD10 codes that might
be associated with an exacerbation of COPD hospital ad-
mission (J10-J18 “influenza & pneumonia”; J20-J22 “other
acute lower respiratory infections”; J40–47 “Chronic lower
respiratory disease”; J96 “Respiratory failure, not classified
elsewhere”). For this endpoint patients were followed up
until their first hospitalisation event. As a sensitivity ana-
lysis, we also considered all respiratory admission (ICD10
code J00 – J99) which is available in Additional file 1.
Covariates
Covariates considered in the analysis consisted of other
factors that could be potential confounders. These were:
(1) Demographics (age, sex, social deprivation score, vac-
cination status, smoking history and Body Mass Index
(BMI)); (2) Respiratory medication (inhaled corticoste-
roids, long acting beta-2 agonists, long acting antimuscari-
nics and other COPD specific medication (theophylline,
aminophylline & carbocisteine); (3) Disease history: Car-
diovascular Disease (CVD): primary prevention - hyper-
tension (defined as on any anti-hypertension drug;
treatment) and dyslipidaemia (defined as serum total chol-
esterol > 5mmol/L). CVD history - myocardial infarction,
heart failure, stroke, peripheral vascular disease (defined
as hospitalization from the SMR1 database). Renal disease
was defined as having serum creatinine ≥220 μmol/l [17];
(4) Charlson Comorbidity Index [18]; a measure of mul-
tiple co-morbidity derived from hospitalisation (SMR01)
data and (5) Scottish Index of Multiple Deprivation
(SMID), this is a measure of socioeconomic status that is
assigned to study subjects at a postcode level.
GOLD severity stage (2014)
This was established at the first qualifying visit and at all
subsequent visits, using the patients’ risk of exacerbation
and symptoms (Fig. 1).
Risk of exacerbation was based on two criteria:
1. Airflow limitation (from TARDIS spirometry –
based on the current FEV1 expressed as a
percentage of predicted FEV1.
2. Exacerbation history in the previous year. This
involved two components:
a. The prescription of short courses of oral
corticosteroids with or without antibiotics was
used as a surrogate measure for exacerbation
(derived from the prescribing data and considered
an event if a dispensed prescription was for a
course of oral prednisolone in which the total
dose was in excess of 150mg AND where the
daily dose of prednisolone (where known) was
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equal to or greater than 30mg). This definition
was subject to a sensitivity analysis looking at the
consistency of any findings where prednisolone
was co-prescribed with pre-determined antibiotics
(amoxicillin, co-amoxiclav, doxycycline and
clarithromycin).
b. SMR01 hospitalisation, where the patient was
admitted with a primary coded admission likely
to be an acute COPD exacerbation (ICD10 J44
code) in the year prior to the visit. Again, this
definition was subject to a sensitivity analysis to
include a broader array of codes that might be
associated with an exacerbation of COPD
requiring hospital admission (J10-J18 “influenza
& pneumonia”; J20-J22 “other acute lower
respiratory infections”; J40–47 “Chronic lower
respiratory disease”; J96 “Respiratory failure, not
classified elsewhere”).
Symptoms were based on the modified MRC dys-
pnoea score (collected at each TARDIS visit). Based on
all these criteria each visit had a GOLD severity stage
assigned to it. The risk of exacerbation and symptoms
was re-calculated approximately every 12 months (at
each annual TARDIS visit) to calculate a “current”
GOLD severity stage (2014). Where two visits occurred
within a short space of time (within 3-months of each
other) the visit showing the best spirometry data was
used in the analysis. As a sensitivity analysis, this re-
striction was removed (i.e. with no minimum duration
between visits specified) and broadened (to a minimum
of 6-month between visits). Previous cohort studies
have shown that GOLD stages B and C frequently have
the least patients within them, and that the association
with mortality in these groups overlaps. For these rea-
sons, these groups were combined for the main analysis
although a sensitivity analysis using all four GOLD
2014 stages was done.
Change of GOLD severity stage
When considering how GOLD severity stage could
change with time, a number of contingencies were pos-
sible. Tables 1 and 2 show the various classification sys-
tems that were trialled.
 Table 1 covers all possible change contingencies.
 GOLD stages B and C are the least common
classification and their association with poor
outcomes has overlapped in previous cohorts. An
analysis with these 2 groups combined into one as
shown in Table 2 was carried out.
Statistical analysis
For initial analyses, a univariate non-time dependent
analysis was used with patients followed up from the
second of two visits until death, event or censored, with
covariates taken at baseline only. This analysis used
Kaplan Meier survival curves & log rank tests.
A Cox regression model using time-dependant analysis
was used to explore the relationship between changing
GOLD stage and the primary and secondary outcomes.
This analysis took into account the fact that patients may
change their GOLD severity during follow-up and allows
the risk to be calculated using these continuously updated
covariates. The time dependent variables (GOLD category)
was updated at the time of each visit. Both univariate and
multivariate analyses was carried out. The univariate ana-
lysis only takes into account the patients’ current and pre-
vious GOLD criteria. The multivariate analysis included all
covariates considered to be potential confounders in an at-
tempt to establish the true effect.
For both approaches, follow up started from the patients
second qualifying visit as prior to this the patient had no
baseline data against which to have changed from. For
mortality outcomes, patients were followed up until death
or censoring. For the respiratory hospitalisation outcome,
patients were followed up until their first event only or
censoring. Missing data were present for some covariates
for a small number of patients (72 subjects with missing
smoking history and 65 subjects with no socioeconomic
status assigned). As these represented a small proportion
of the cohort (less than 3% in total), it was assumed that
these were completely missing at random and a complete
case analysis performed for multivariate analyses.
To establish if there were any relevant interactions in
the multivariate analyses, two-way interactions terms
were modelled incorporating GOLD category change
and other key covariates of interest, particularly age and
sex. No such relevant interaction terms were found, and
no interaction term were used in the final models.
Variables were included in the statistical models as po-
tential predictors of the outcome events. All statistical
analyses were carried out using SAS (version 9.4).
Table 1 All possible GOLD severity stage (2014) changes
between visits
A→ A B→ A C→ A D→ A
A→ B B→ B C→ B D→ B
A→ C B→ C C→ C D→ C
A→D B→ D C→D D→D
Table 2 GOLD severity stage (2014) changes between visits
(categories B & C combined)
A→ A BC→ A D→ A
A→ BC BC→ BC D→ BC
A→D BC→D D→ D
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Studies of this nature frequently have to make assump-
tions regarding definitions of exclusions, exposures and
outcomes. As detailed above, where such assumptions
were made, these were the subject of sensitivity analyses
which tested the reliability of any such arbitrary deci-
sions that were made.
Results
Figure 2 shows the derivation of the study cohort. The
main analysis cohort consisted of 4885 patients who had
a total of 21,348 TARDIS visits during follow-up. The
cohort was 51.4% female and had mean age of 67.3 years.
There was a significant history of smoking amongst the
study cohort with a median of 68.0 pack-years exposure.
The cohort was disproportionately from more deprived
backgrounds and the mean BMI was 26.3 (standardised
deviation 5.3). A summary of the cohort characteristics
is shown in Table 3.
There was a total of 31,891 years of follow-up to the
primary endpoint (a median of 6.6 years per patient) and
Fig. 2 CONSORT diagram showing derivation of study cohort
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a median 1.1 years between consecutive TARDIS visits.
There was a median of 4 visits per patient (minimum 2,
maximum 12). The GOLD classification of each visit in
the main cohort is shown in the Table 4.
In the primary analysis (all-cause mortality), there
were 1530 primary outcome events. For the secondary
outcomes there were 712 respiratory deaths and 1629
first hospitalisations. Figure 3 shows a description of the
primary and secondary outcomes stratified by GOLD
classification following both univariate and multivariate
analyses. In general, it is seen that GOLD category A has
the best survival, GOLD D has the worst outcomes, and
GOLD B & C were in between with overlapping survival
curves and similar hospitalisation outcomes. As GOLD
C was a small group with similar outcomes to B, it was
decided to pool these patients with the GOLD B patients
for analysis.
GOLD severity changes were then elucidated. A sum-
mary of all the changes in GOLD category for the main
analysis cohort is shown in Table 5. This shows the
change in GOLD classified between the first two visits
(with one change for each patient), and the change for
all visits (with potentially multiple visits per patient).
Table 6 shows the association between GOLD se-
verity changes and the primary outcome (all-cause
mortality) and secondary outcomes in a multivariate
time-dependent analyses. In general, it shows that
moving from a better to a worse GOLD category is
associated with worse all-cause mortality, respiratory
mortality and respiratory morbidity. There is also
evidence of a “dose response” with larger changes in
category being associated with a greater degree of
risk.
The results from the various sensitivity analyses are
given in the Additional file 1. These show the study find-
ings to be robust to the various assumptions that where
made when compiling the datasets and assigning GOLD
stage categories.
Table 3 Baseline characteristics
n = 4885
Age (years) 68 (60–75)
Female 2505 (51.3%)
BMI (kg/m2)a 25.7 (22.7–29.2)
Social deprivationa
1 - most deprived 2091 (43.4%)
2 950 (19.7%)
3 547 (11.3%)
4 772 (16.0%)
5 - most affluent 460 (9.5%)
Ruralitya
Large Urban Areas 4357 (90.4%)
Other Urban Areas 164 (3.4%)
Small Towns 19 (0.4%)
Accessible Rural 280 (5.8%)
History of hypertension medication 2363 (48.4%)
History of dyslipidaemia 1645 (33.7%)
History of renal disease 99 (2.0%)
History of cardiovascular events 766 (15.7%)
History of cardiovascular prevention 3101 (63.5%)
Charlson Score
0 3062 (62.7%)
1 1173 (24.0%)
2 393 (8.0%)
3 156 (3.2%)
4 70 (1.4%)
5 22 (0.5%)
over 6 9 (0.2%)
Smoking history (pack years) 38 (25–50)
Current smoking statusa
Current 1188 (24.3%)
Quittingb 1551 (31.8%)
Former 1830 (37.5%)
Never 310 (6.4%)
FEV1(litres) 1.54 (1.15–2.05)
FEV1 as percentage of predicted 68.1 (53.7–81.6)
Modified MRC dyspnoea score 1 (1–2)
Baseline GOLD stage
A 2420 (49.5%)
B 1268 (26.0%)
C 476 (9.7%)
D 721 (14.8%)
BMI body mass index, FEV1 forced expiratory volume in one second, MRC
Medical Research Council, GOLD Global Initiative for Chronic Obstructive
Lung Disease
aData missing for some patients: BMI for 139, social deprivation & rurality for
65, smoking pack years for 72, current smoking status for 6
b“quitting” means the patient is a current smoker who is either trying to or is
contemplating giving up smoking
Data are median (IQR) or n (%)
Table 4 GOLD severity stage (2014) classification across all visits
GOLD
category
First visit (i.e. 1 per patient) All visits (up to 12 per patient)
n (visits) % n (visits) %
A 2420 49.5 9741 45.6
B 1268 26.0 5344 25.0
C 476 9.7 2194 10.3
D 721 14.8 4069 19.0
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Discussion
A major aim of the change in GOLD classification to
include symptoms and exacerbation history was the
appreciation that spirometry alone did not capture the
full complexity and heterogeneity of the COPD patient
[19–21]. Although guiding pharmacotherapy was not
the primary intention, this is now a core part of the
guidance [2]. Guideline concordant therapy is difficult
Fig. 3 Univariate and multivariate (“adjusted”) Kaplan-Meier survival plots showing time to all-cause mortality from initial TARDIS visit. a, c
& e show univariate plots, b, d & f are “adjusted” multivariate plots derived from a non-time dependent Cox model. The top two plots a
& b are for the primary outcome (all-cause mortality); the middle two c & d for respiratory specific mortality; and the bottom two e & f
for respiratory hospitalisation
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without understanding the propensity of patients to
change severity stage. Understanding the stage natural
progression and the associations with outcome of this
is important to manage patients as without this under-
standing, changes to patients’ severity stage can make
optimal management difficult.
In this manuscript, we describe the largest longitudinal
cohort looking at variability of GOLD severity stage over
time and for the first to describe the association of GOLD
severity stage change with poor outcomes. As seen in
other cohorts, GOLD severity stage C is the least common
severity stage in our study. Our study confirms that
GOLD A severity has the best survival, GOLD D has the
worst outcomes [22], and that outcomes of patients with
GOLD B and C severity lie in between and often overlap
[5–7]. In keeping with previous studies, we show that over
half patients’ severity stage remains stable [10]. Looking at
those patients over time we show that GOLD stage A pa-
tients who remain in that stage have the best outcomes in
terms of hospitalisations and mortality. Patients whose se-
verity stage worsens have worse outcomes with a “dose ef-
fect” present such that worse outcomes are seen in those
whose severity stage deteriorates by more than one step,
for example A to D, when compared to those whose sever-
ity stage only worsens by one stage, for example A to B, or
B to C, or A to BC). Patients who move from stage BC to
A have worse outcomes than those who are only ever
stage A, implying the latter have more stable disease and
hence better outcomes. The converse is true at the other
end of the severity scale. Interestingly, we have shown that
improvement of COPD severity stage as described by the
GOLD 2014 classification was associated with improved
all-cause mortality, improved respiratory specific mortality
and respiratory hospitalisations when compared to those
individuals who remain in the same severity group. Our
results may seem axiomatic; the only way to worsen one’s
Table 5 Summarised changes in GOLD category
GOLD category
change
Change for first
two visits only
(i.e. 1 per patient)
Change between subsequent
visits for all visits
(up to 11 per patient)
n (visit pairs) % n (visit pairs) %
A→ A 1819 37.2 5802 35.2
A→ B 369 7.6 1180 7.2
A→ C 144 3.0 546 3.3
A→D 88 1.8 237 1.4
B→ A 340 7.0 985 6.0
B→ B 704 14.4 2375 14.4
B→ C 44 0.9 139 0.8
B→ D 180 3.7 609 3.7
C→ A 119 2.4 404 2.5
C→ B 34 0.7 115 0.7
C→ C 221 4.5 765 4.7
C→D 102 2.1 434 2.7
D→ A 50 1.0 130 0.8
D→ B 124 2.5 406 2.5
D→ C 86 1.8 268 1.6
D→D 461 9.4 2068 12.6
With GOLD categories B & C combined
A→ A 1819 37.2 5802 35.2
A→ BC 513 10.5 1726 10.5
A→D 88 1.8 237 1.4
BC→ A 459 9.4 1389 8.4
BC→ BC 1003 20.5 3394 20.6
BC→ D 282 5.8 1043 6.3
D→ A 50 1.0 130 0.8
D→ BC 210 4.3 674 4.1
D→D 461 9.4 2068 12.6
Table 6 Survival analyses showing time to primary endpoints outcome (all-cause mortality) and secondary endpoints (respiratory
specific mortality and respiratory hospitalisation) in a time-dependent multivariate analyses
GOLD Category
Change
Primary outcome Secondary outcome
Multivariate time dependent analyses Respiratory specific mortality Respiratory hospitalisation
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
A→ A 1.00 ref 1.00 ref 1.00 ref
A→ BC 1.66 (1.34–2.07) <.0001 2.28 (1.50–3.46) 0.0001 1.62 (1.31–2.01) <.0001
A→D 2.08 (1.30–3.32) 0.0022 4.68 (2.37–9.23) <.0001 3.13 (2.13–4.60) <.0001
BC→ A 1.58 (1.23–2.02) 0.0003 2.27 (1.43–3.60) 0.0005 1.44 (1.13–1.83) 0.0034
BC→ BC 1.98 (1.67–2.35) <.0001 3.27 (2.34–4.55) <.0001 2.32 (1.97–2.73) <.0001
BC→ D 3.21 (2.61–3.94) <.0001 7.51 (5.30–10.66) <.0001 4.81 (3.98–5.82) <.0001
D→ A 1.31 (0.61–2.78) 0.4890 0.79 (0.11–5.70) 0.8112 1.01 (0.42–2.46) 0.9755
D→ BC 2.96 (2.32–3.78) <.0001 7.38 (4.99–10.93) <.0001 4.12 (3.29–5.17) <.0001
D→D 4.31 (3.64–5.10) <.0001 12.86 (9.47–17.46) <.0001 5.87 (4.97–6.92) <.0001
In a model that also adjusted for age, sex, smoking history, BMI, use of COPD related medication at baseline, history of cardiovascular events, history of
cardiovascular protecting therapies, renal failure, Charlson comorbidity index and socioeconomic status
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GOLD severity group is either by having more symptoms
and/or more exacerbations and both factors have been re-
peatedly demonstrated to be associated with increased risk
of mortality [13]. However, while the effects of individual
risk factors have been previously studied, this is the first
time such a change has been shown within a combined se-
verity classification.
The strengths of this study are that data were collected
in routine care with minimal exclusions, which increases
the likelihood that the results will be applicable to other
populations. This is significant as most patients with
COPD are managed in primary rather than secondary
care. The primary-care based nature of our cohort is
demonstrated by the significant number of patients with
GOLD stage A disease, unlike hospital generated cohorts
which are less likely to be generalizable to the broader
COPD population. Another strength is the significant
representation of women which is not always the case in
hospital-based cohorts.
Weaknesses of this study include the ability to only as-
sess symptoms using mMRC dyspnoea score. This is in
line with other reported cohorts [10]. Despite data being
collected prospectively according to predefined criteria,
follow-up data are observational and therefore prone to
the weaknesses of this type of study. Another important
consideration is that the latest GOLD classification (2017)
separates the spirometry and exacerbation classifications,
thus creating a total of 16 potential severity classifications
[23]. This means that there are now 256 potential stage
shifts (including stability). We attempted repeating our
analyses with this classification however there were too
many groups with very few or no individuals making
models uninterpretable. Though we attempted to limit
bias by adjusting for other potential confounders, bias due
to unrecorded factors may remain.
Conclusions
In summary, our data based on a large cohort of
well-characterized community COPD patients provide
important information on the assessment of patients with
COPD. Using the new multidimensional GOLD classifica-
tion, we showed that disease progression as defined by
worsening GOLD stage is associated with poorer out-
comes, whilst the reverse is true for improvement.
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